S/MARter Immunotherapies
Our Products
Cancer Vaccines
Tcelltech has also developed peptide vaccines targeting the two most common clonal driver mutations in incurable brain tumors (IDH1R132H and H3K27M).
Our IDH1 SCA-VAC has completed Phase I trial (32 patients, 21 grade 3, 11 grade 4), meeting both primary endpoints with very promising results (Reference: https://www.nature.com/articles/s41586-021-03363-z).
A subsequent randomized Phase 2 clinical trial is expected to start in 2026.
Our H3 SCA-VAC is currently in Phase I development in combination with Atezolizumab after successful first-in-human dosing (Reference: https://www.nature.com/articles/s41591-023-02555-6).
First data of the combination trial will be published in 2026.
Tumor-targeting T cell receptors
TCT-001 is a first-in-class T cell therapy for patients with glioblastoma employing T cells engineered with a proprietory T cell receptor targeting a glioblastoma antigen.
After successful preclinical development (Reference: https://www.nature.com/articles/s41467-025-56547-w) TCT-001 engineered with our nanoSMAR platform will start phase 1 testing in 2026.
© 2025 Tcelltech GmbH. All rights reserved.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.